Johnson & Johnson Reports Lower Mortality Rates for Impella Heart Pump Support
Johnson & Johnson (JNJ) has released results from three clinical analyses indicating that patients receiving Impella heart pump support during high-risk coronary procedures experienced lower mortality rates than those reported in the recent CHIP-BCIS3 clinical trial. The findings suggest improved patient outcomes when utilizing this specific mechanical circulatory support during complex interventions. The data, presented at a medical conference, provides critical evidence regarding the efficacy and safety profile of the Impella device in high-risk settings. This development could influence clinical guidelines and bolster market confidence in JNJ's cardiovascular technology portfolio.
Tickers: $JNJ
Topics: cardiovascular health clinical trial results medical devices mortality rates